388 related articles for article (PubMed ID: 23625205)
1. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
Wang XJ; Feng CW; Li M
Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
[TBL] [Abstract][Full Text] [Related]
2. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
[TBL] [Abstract][Full Text] [Related]
3. High Glucose Up-regulates ADAM17 through HIF-1α in Mesangial Cells.
Li R; Uttarwar L; Gao B; Charbonneau M; Shi Y; Chan JS; Dubois CM; Krepinsky JC
J Biol Chem; 2015 Aug; 290(35):21603-14. PubMed ID: 26175156
[TBL] [Abstract][Full Text] [Related]
4. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.
Yang CL; Jiang FQ; Xu F; Jiang GX
Tumour Biol; 2012 Oct; 33(5):1535-41. PubMed ID: 22581584
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis.
Tanaka H; Yamamoto M; Hashimoto N; Miyakoshi M; Tamakawa S; Yoshie M; Tokusashi Y; Yokoyama K; Yaginuma Y; Ogawa K
Cancer Res; 2006 Dec; 66(23):11263-70. PubMed ID: 17145871
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3ζ up-regulates hypoxia-inducible factor-1α in hepatocellular carcinoma via activation of PI3K/Akt/NF-кB signal transduction pathway.
Tang Y; Lv P; Sun Z; Han L; Luo B; Zhou W
Int J Clin Exp Pathol; 2015; 8(12):15845-53. PubMed ID: 26884855
[TBL] [Abstract][Full Text] [Related]
8. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
Zheng X; Jiang F; Katakowski M; Zhang ZG; Lu QE; Chopp M
Cancer Biol Ther; 2009 Jun; 8(11):1045-54. PubMed ID: 19395875
[TBL] [Abstract][Full Text] [Related]
9. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
Jiao M; Nan KJ
Int J Oncol; 2012 Feb; 40(2):461-8. PubMed ID: 21922131
[TBL] [Abstract][Full Text] [Related]
10. Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α.
Zhao J; Lin E; Cai C; Zhang M; Li D; Cai S; Zeng G; Yin Z; Wang B; Li P; Hong X; Chen J; Zou B; Li J
Drug Des Devel Ther; 2022; 16():3197-3213. PubMed ID: 36158238
[TBL] [Abstract][Full Text] [Related]
11. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
Mu H; Yu G; Li H; Wang M; Cui Y; Zhang T; Song T; Liu C
Cell Oncol (Dordr); 2021 Oct; 44(5):1151-1166. PubMed ID: 34339013
[TBL] [Abstract][Full Text] [Related]
12. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
14. HIF-1α promotes inflammatory response of chronic obstructive pulmonary disease by activating EGFR/PI3K/AKT pathway.
Zhang HX; Yang JJ; Zhang SA; Zhang SM; Wang JX; Xu ZY; Lin RY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6077-6084. PubMed ID: 30280794
[TBL] [Abstract][Full Text] [Related]
15. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
[TBL] [Abstract][Full Text] [Related]
16. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
17. The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma.
Cui SY; Huang JY; Chen YT; Song HZ; Huang GC; De W; Wang R; Chen LB
Cell Cycle; 2013 Sep; 12(17):2849-66. PubMed ID: 23966163
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
19. Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells.
Xu LF; Ni JY; Sun HL; Chen YT; Wu YD
World J Gastroenterol; 2013 Mar; 19(11):1749-59. PubMed ID: 23555163
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha.
Adamski J; Price A; Dive C; Makin G
PLoS One; 2013; 8(6):e65304. PubMed ID: 23785417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
